Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $22.9000 (-3.05%) ($22.4500 - $23.5700) on Wed. Aug. 12, 2015. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.6% (three month average) | RSI | 8 | Latest Price | $22.9000(-3.05%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -1.5% a day on average for past five trading days. | Weekly Trend | ADMS declines -5.6% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(34%) IBB(32%) IWM(22%) XOP(21%) XLV(20%) | Factors Impacting ADMS price | ADMS will decline at least -1.8% in a week (0% probabilities). VIXM(-15%) BNDX(-10%) TLT(-8%) SHY(-7%) UUP(-5%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.8% (StdDev 3.6%) | Hourly BBV | 0 () | Intraday Trend | -2.8% | | | |
|
1 - 5 Day Possible Target | $10.07(-56.03%) | Resistance Level | $25.61 | 5 Day Moving Average | $23.59(-2.92%) | 10 Day Moving Average | $24.14(-5.14%) | 20 Day Moving Average | $25.61(-10.58%) | To recent high | -23.2% | To recent low | 31.4% | Market Cap | $648m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |